A2M Price sensitive 19 Nov 2026, 7:30 AM

China IMF and FY27 outlook update

The a2 Milk Company Ltd

a2 Milk Company Updates China IMF Recovery and FY27 Outlook

Key points

  • China IMF offtake has recovered to ~50% of pre-supply chain disruption levels
  • FY27 revenue and EBITDA expected to grow, supported by new markets and product innovation
  • IMF sales expected to be similar to FY26, with recovery in 2H27

Full summary

The a2 Milk Company has provided an update on its China Infant Milk Formula (IMF) recovery and its FY27 outlook. The company has recovered to approximately 50% of pre-supply chain disruption levels in China IMF offtake. For FY27, the company expects revenue and EBITDA growth, supported by product innovation, new markets, and a2 Pååkeno profitability improvement. IMF sales are expected to remain similar to FY26, with recovery in the second half of FY27. The company also expects underlying EBITDA margin to be approximately 15%, with depreciation and amortization of around $20 million.

Guidance

FY27 revenue growth expected in mid single digits, EBITDA margin approximately 15%

Outlook

The company expects total IMF sales to be broadly similar to FY26, with recovery in the second half of FY27. Group revenue and EBITDA are expected to be materially weighted to 2H27.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in